SIGA Technologies is an American pharmaceutical company specializing in the treatment of infectious diseases. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
SIGA Technologies news
06.05.2022
SIGA Technologies' GAAP net income for 3 months of 2022 was $361,049 thousand, down 2.2 times from $812,105 thousand in the previous year. Revenue increased 2.2 times to $10.539 million from $4.814 million a year earlier.
Source: 
investor.siga.com
investor.siga.com
05.05.2022
The Board of Directors of SIGA Technologies has declared a special dividend of $0.45 per share. The last day to purchase securities to receive the dividend is May 12, 2022. The annual dividend yield could be 6.66%.
Source: investor.siga.com
investor.siga.com
04.03.2022
SIGA Technologies' GAAP net income for 2021 was $69.451 million, up 23.3 percent from $56.342 million in the prior year. Revenue increased 7% to $133.671 million from $124.959 million a year earlier.
Source: investor.siga.com
investor.siga.com
10.01.2022
SIGA Technologies has received approval from the EMA to market tecovirimat in all EU member states, as well as Norway, Iceland and Liechtenstein. The drug is indicated for the treatment of smallpox, monkeypox, cowpox and complications after smallpox vaccination.
Source: investor.siga.com
investor.siga.com
General information
| Company name | SIGA Technologies |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 31 East 62nd Street New York, NY 10065 United States |
| Mailing address | 31 East 62nd Street New York, NY 10065 United States |
| Website | investor.siga.com |
| Information disclosure | www.sec.gov |
English (US) 